WhatPeptide

AOD-9604

A modified growth hormone fragment investigated for lipolysis-related effects without full GH receptor profile. Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

Preliminary evidence FDA Category 2 GH Fragment

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

FDA Category 2 — compounding availability may be limited.

Half-life

Estimated 1-2 hours

Dosage range

250-500 mcg daily (published research context)

Administration

Subcutaneous injection

Research level

Preliminary

How AOD-9604 works

AOD-9604 is derived from the C-terminal fragment of human growth hormone and has been investigated for adipose metabolism signaling. Early studies suggested potential effects on lipolysis and inhibition of lipogenesis. Regulatory status remains limited and efficacy findings are mixed.

Also known as: HGH Fragment 176-191

Research relevance

Fat Loss
Some relevance 40
GH Boost
Some relevance 30
Anti-Aging & Longevity
Some relevance 25
Muscle Growth
Some relevance 20
Recovery & Healing
Some relevance 20

Side effects & safety

Injection-site irritation Headache Transient nausea

Contraindications

Pregnancy
Uncontrolled endocrine disease

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is AOD-9604? +
A modified growth hormone fragment investigated for lipolysis-related effects without full GH receptor profile. Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain. Its mechanism of action is based on preliminary or early-stage research.
What is AOD-9604 researched for? +
AOD-9604 has the strongest research relevance for Fat Loss, GH Boost, Anti-Aging & Longevity. Evidence is based on preliminary or early-stage research.
What are the side effects of AOD-9604? +
Reported side effects include Injection-site irritation, Headache, Transient nausea. Key contraindications: Pregnancy; Uncontrolled endocrine disease.
Is AOD-9604 FDA approved? +
AOD-9604 is classified as FDA Category 2, meaning compounding availability may be limited.
How is AOD-9604 administered? +
AOD-9604 is typically administered via subcutaneous route. Researched dosage range: 250-500 mcg daily (published research context). Half-life: Estimated 1-2 hours.

Explore similar peptides

HGH Fragment 176-191

Preliminary evidence

GH Fragment

HGH Fragment 176-191 is the C-terminal peptide fragment of human growth hormone specifically associated with lipolytic activity, studied for fat loss without the growth-promoting or insulin-desensitizing effects of intact HGH. It is distinct from AOD-9604 which is a modified version with additional structural changes.

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

GHRP-2

Moderate evidence

Growth Hormone Releasing Peptide

A potent synthetic GH secretagogue with human endocrine data demonstrating acute GH pulse stimulation.

GHRP-6

Moderate evidence

Growth Hormone Releasing Peptide

An early GH secretagogue peptide commonly associated with increased appetite alongside GH pulse stimulation.